Company news
uniQure N.V. news in 2025
uniQure N.V.'s news releases, calls and decks from 2025, newest first.
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
December 3, 2025
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 9, 2025
uniQure to Announce Third Quarter 2025 Financial Results
November 5, 2025
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
September 28, 2025
uniQure Announces Pricing of Upsized $300 Million Public Offering
September 24, 2025
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
September 23, 2025
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
September 23, 2025
uniQure Announces $200 Million Proposed Public Offering
September 23, 2025
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
September 4, 2025
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
July 28, 2025
uniQure to Announce Second Quarter 2025 Financial Results
July 21, 2025
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
June 10, 2025
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
May 28, 2025
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
May 8, 2025
uniQure to Announce First Quarter 2025 Financial Results
May 4, 2025
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
April 16, 2025
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
February 26, 2025
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
February 2, 2025
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
January 29, 2025
uniQure Announces Pricing of its Public Offering
January 7, 2025
uniQure Announces Proposed Public Offering
January 6, 2025
Calls in 2025
Decks in 2025
- Corporate Update (September 2025)
Corporate update · 29 slides · Sep 24, 2025